What are the treatment options for a patient with Respiratory Syncytial Virus (RSV) infection, particularly for high-risk populations such as infants, older adults, or those with compromised immune systems?

Treatment of Respiratory Syncytial Virus (RSV) Infection

For most patients with RSV infection, treatment is entirely supportive—there is no routine antiviral therapy indicated, and management focuses on maintaining adequate oxygenation and hydration. 1, 2, 3

General Management Principles for All Patients

Supportive Care (Cornerstone of Treatment)

• Maintain oxygen saturation above 90% with supplemental oxygen as needed 1, 2, 3
• Ensure adequate hydration through oral intake, or use nasogastric/intravenous routes if the patient cannot maintain oral hydration 1, 2, 3
• Use acetaminophen or ibuprofen for fever and pain management 1
• Consider nasal saline irrigation for symptomatic relief in adults with upper respiratory symptoms 1

What NOT to Use (Critical to Avoid)

• Do NOT use bronchodilators routinely—they provide no benefit in RSV bronchiolitis 1, 2, 3
• Do NOT use corticosteroids—they are not recommended for RSV management 1, 2, 3
• Do NOT use antibiotics unless there is specific evidence of bacterial co-infection 1, 2
• Do NOT use chest physiotherapy—it is ineffective 2
• Do NOT use nebulized hypertonic saline or epinephrine routinely 2, 3
• Do NOT use palivizumab for treatment—it is only for prevention in high-risk infants, never for treating active infection 1

Infection Control (Essential to Prevent Transmission)

• Hand hygiene is the single most important measure to prevent RSV transmission 1, 4
• Use alcohol-based hand rubs before and after patient contact 1, 4
• Wear gloves when handling patients or respiratory secretions, changing gloves between patients 5
• Wear gowns if clothing could be soiled by respiratory secretions 5, 4
• Implement contact isolation or cohorting of RSV-positive patients 4
• Restrict healthcare workers with active upper respiratory symptoms from caring for high-risk patients 5

---

Treatment for High-Risk and Immunocompromised Populations

Who Qualifies as High-Risk

• Hematopoietic stem cell transplant (HSCT) recipients 1, 6
• Solid organ transplant recipients 1
• Patients with profound lymphopenia (<100 cells/mm³) 1
• Patients on active chemotherapy for malignancy 1
• Patients with severe combined immunodeficiency (SCID) 1
• Mechanically ventilated infants with documented severe RSV infection 6

Ribavirin Therapy (Only Antiviral Option)

Ribavirin is the only antiviral treatment for RSV, but its use is restricted to severely immunocompromised patients—particularly HSCT recipients with RSV lower respiratory tract infection. 1, 6

Indications for Ribavirin

• HSCT patients with RSV lower respiratory tract infectious disease (LRTID) or at high risk for progression 1, 4
• Severely immunocompromised patients with documented RSV lower respiratory tract infection 1, 6
• Mechanically ventilated infants with severe documented RSV infection (FDA-approved indication) 6

Ribavirin Administration Routes

Aerosolized Ribavirin:

• Primary option for mechanically ventilated patients 1, 6
• FDA-approved for hospitalized infants and young children with severe lower respiratory tract RSV infection 6
• Should only be used by physicians familiar with ventilator administration 6

Systemic Ribavirin (Oral or IV):

• For patients unable to take oral medication or when aerosolized form is not feasible 1
• Dosing schedule: 1
  • Day 1: 600 mg loading dose, then 200 mg every 8 hours
  • Day 2: 400 mg every 8 hours
  • Day 3 onward: Increase to maximum 10 mg/kg every 8 hours
  • Renal adjustment: For CrCl 30-50 mL/min, maximum 200 mg every 8 hours

Monitoring for Ribavirin Adverse Effects

• For aerosolized ribavirin: Monitor for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function 1
• For systemic ribavirin: Monitor for hemolysis, abnormal liver function tests, and declining renal function 1
• Avoid environmental exposure in pregnant healthcare workers due to teratogenic effects 1

Combination Therapy for HSCT Patients

• Consider combining ribavirin with intravenous immunoglobulin (IVIG) or anti-RSV-enriched antibody preparations for allogeneic HSCT patients with RSV LRTID 1, 4

Timing Considerations

• Defer conditioning therapy for patients with RSV respiratory tract infection planned for allogeneic HSCT 1, 4
• Consider deferring chemotherapy for patients with RSV infection scheduled for hemato-oncological treatment 1
• RSV infection should be documented by rapid diagnostic method before or during the first 24 hours of ribavirin treatment 1, 6

---

Management of Respiratory Distress and Escalation of Care

Oxygen Therapy Options

• Standard supplemental oxygen for SpO2 <90% 1, 2
• High-flow nasal oxygen (HFNO) may be considered in selected patients with hypoxemic respiratory failure, but only in monitored settings with personnel capable of intubation 1, 7
• Non-invasive ventilation (NIV) is NOT recommended due to high failure rates and risk of aerosol generation 1

Criteria for ICU Transfer

• Failure to maintain SaO2 >92% in FiO2 >60% 1
• Shock or severe respiratory distress with rising PaCO2 (>6.5 kPa) 1
• Development of apnea or persistent grunting 1
• Worsening respiratory distress despite supplemental oxygen 1

When to Consider Early Intubation

• If respiratory distress worsens or oxygen requirements cannot be met with standard supplementation, consider early intubation and invasive mechanical ventilation 1

---

Prevention Strategies

RSV Vaccination (Adults and Pregnant Women)

All adults aged ≥60 years should receive RSV vaccination, and adults aged 50-59 years with risk factors (chronic respiratory disease, heart disease, kidney disease, diabetes, immunocompromised status, obesity, neurological conditions, or long-term care residence) should also be vaccinated. 5, 8, 4

Available Vaccines

• RSVPreF3 (Arexvy, GlaxoSmithKline): 82.6% efficacy against RSV-associated lower respiratory tract disease in first season, with protection maintained for at least three seasons 8
• RSVpreF (Abrysvo, Pfizer): 65.1% efficacy in first season, with protection maintained for at least two seasons 8
• mRESVIA (mRNA-1345): Also approved for adults ≥60 years 5

Administration

• Single intramuscular dose, preferably between September and November before RSV season 8, 4
• Can be co-administered with seasonal influenza vaccine at different injection sites 8
• Previous RSV infection does not contraindicate vaccination 8

Maternal Vaccination

• RSV vaccination (Abrysvo) for pregnant individuals at 32-36 weeks' gestation provides passive protection to infants from birth through 6 months of age 4, 9
• Use seasonal administration (typically September-January in most of the United States) 5
• Efficacy >80% in first 3 months of life to protect infant from severe RSV-associated lower respiratory disease 9

Palivizumab Prophylaxis (Infants Only—NOT Treatment)

Palivizumab is ONLY for prevention in high-risk infants—it has no therapeutic benefit for treating established RSV infection. 1

Indications for Palivizumab

• Infants born ≤28 weeks gestation who are <12 months old at start of RSV season 1
• Infants with bronchopulmonary dysplasia requiring medical treatment within previous 6 months 1
• Children with hemodynamically significant congenital heart disease 1
• Patients with SCID or suspected SCID during RSV season 1

Dosing

• 15 mg/kg intramuscularly monthly throughout RSV season, maximum 5 doses per season 1
• Reduces RSV hospitalization by 45-55% in high-risk populations 1

Universal Prevention Measures

• Avoid tobacco smoke exposure completely—it is a controllable risk factor that increases RSV hospitalization risk 1, 4
• Limit exposure to crowds and group childcare during RSV season (November-March in most regions) 1
• Keep infants away from sick contacts 1
• Encourage breastfeeding to decrease risk of lower respiratory tract disease 1, 4
• Ensure influenza vaccination for infants starting at 6 months and all household contacts 1

---

Common Pitfalls to Avoid

• Overusing antibiotics when there is no evidence of bacterial co-infection—RSV is viral and does not require antibiotics 1
• Continuing bronchodilator therapy without documented clinical improvement—these are ineffective in RSV 1
• Using palivizumab to treat active RSV infection—it is only for prevention 1
• Inadequate infection control measures leading to nosocomial transmission—hand hygiene is critical 1, 4
• Routine use of diagnostic testing in outpatient bronchiolitis where management will be supportive regardless—testing is unnecessary 1